araag2/HINT huggingface dataset:
Clinical trial NCT00606177 (phase 3, status: completed)
Conditions: bipolar i disorder
ICD codes: F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76
Drugs: aripiprazole, placebo
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Trial subjects will be men and women of age 18 or above and below the age of 65 who
             will not be turning 65 during the trial.

          -  Subjects have the ability to understand and to provide informed consent to the
             examination, observation, and evaluation processes specified in this protocol, and
             have signed the informed consent form based on a full understanding of the trial.

          -  Subjects who meet DSM-IV-TR criteria for manic or mixed episodes and have been
             diagnosed as having "296.4x Bipolar I Disorder in which the most recent episode was
             manic" or "296.6x Bipolar I Disorder in which the most recent episode was mixed"

          -  Subjects who were enrolled in and have completed Study 003 and who meet the following
             criteria for demonstration of drug efficacy

          -  Subjects demonstrating drug efficacy:

               -  Those subjects who completed Study 003 whose score for CGI-BP Change From
                  Preceding Phase (mania) at the time of evaluation on Day 21 of Study 003
                  (completion) was between 1 (Very much improved) and 3 (Minimally improved)

        Exclusion Criteria:

          -  Subjects presenting with a clinical picture and/or history that is consistent with a
             DSM-IV-TR diagnosis of:

               -  Delirium, dementia, amnestic disorder, or other cognitive disorders

               -  Schizophrenia or other psychotic disorder

               -  Personality disorder

          -  Subjects with psychotic symptoms that are clearly due to another general medical
             condition or direct physiological effects of a substance

          -  Subjects who represent a significant risk of committing suicide

          -  Subjects known to have a complication of allergy to aripiprazole or other
             quinolinone-skeleton compounds

          -  Subjects with a complication of neuroleptic malignant syndrome

          -  Subjects in a state of physical exhaustion accompanied by such conditions as
             dehydration or malnutrition

          -  Subjects with a complication of paralytic ileus

          -  Subjects with a complication of organic brain disorder or convulsive disorder, such as
             epilepsy

          -  Subjects with a complication of diabetes
Clinical trial NCT00504244 (phase 3, status: terminated)
Conditions: systemic lupus erythematosus
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: switch to myfortic, continuation of azathioprine
SMILES: COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C, CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O
Reason stopped: 
    insufficient recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females, aged 18 years and over

          -  Patients meeting the diagnostic criteria for SLE (Appendix 2), according to ACR
             guidelines (including screening for anti-dsDNA (antibody to native DNA in abnormal
             titer))

          -  SLEDAI > 6

          -  Patients treated with maintenance therapy including azathioprine.

          -  Patients who are willing and able to participate in the study and from whom written
             informed consent has been obtained

        Exclusion Criteria:

          -  Creatinine clearance of < 20ml/min

          -  Patients with any clinically significant infection

          -  Patients with known hypersensitivity to myfortic ® or to drugs with similar chemical
             structures

          -  Patients with a history of malignancy of any organ system, treated or untreated,
             within the past 5 years whether or not there is evidence of local recurrence or
             metastases, with the exception of localized basal cell carcinoma of the skin

          -  Patients with SLE active CNS manifestations or a past history of SLE CNS complications
             (e.g. psychosis, grand mal seizures)

          -  Patients who have received prior therapy with mycophenolic acids (MPAs) (e.g. MMF)

          -  Patients who have received an investigational drug within four weeks prior to study
             entry

          -  Females of childbearing potential who are planning to become pregnant, who are
             pregnant and/or lactating, who are unwilling to use effective means of contraception
Clinical trial NCT01364012 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: bevacizumab, carboplatin, paclitaxel, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Locally advanced (Stage IIIb not amenable for combined modality treatment), metastatic
             (Stage IV) or recurrent non-squamous non-small cell lung cancer

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Adequate hematological, renal and liver function

        Exclusion Criteria:

          -  Prior chemotherapy or treatment with another systemic anti-cancer agent for the
             treatment of the participant's current stage of the disease (Stage IIIb, IV or
             recurrent disease)

          -  Mixed non-small cell and small cell tumors or mixed adenosquamous carcinomas with a
             predominant squamous component

          -  Evidence of tumor invading major blood vessels on imaging

          -  Central nervous system (CNS) metastases, even if previously treated

          -  History of hemoptysis in the 3 months prior to enrollment

          -  History or evidence of inherited bleeding diathesis or coagulopathy

          -  Uncontrolled hypertension and/or history of hypertensive crisis or hypertensive
             encephalopathy

          -  Clinically significant cardiovascular or vascular disease

          -  Malignancies other than non-small cell lung cancer within 5 years prior to
             randomization, except for adequately treated carcinoma in situ of the cervix, basal or
             squamous cell skin cancer, or localized prostate cancer or ductal carcinoma in situ
             treated surgically with curative intent
Clinical trial NCT00002895 (phase 3, status: completed)
Conditions: fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer
ICD codes: C57.00, C57.01, C57.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818
Drugs: chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal
             cancer

               -  Achieved complete remission with normal CA 125 after first-line
                  platinum-containing chemotherapy

          -  Prior participation in the following clinical trials is allowed:

               -  MRC-ICON2 (carboplatin vs cyclophosphamide, doxorubicin, and cisplatin for
                  advanced disease)

               -  MRC-ICON3 (paclitaxel with carboplatin in first-line therapy for advanced
                  disease)

               -  MRC-ICON5 (carboplatin and paclitaxel vs triplet and sequential doublet
                  combinations of chemotherapy)

          -  No prior participation in MRC-ICON1 (adjuvant chemotherapy for early-stage ovarian
             cancer)

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  No prior or concurrent malignancy within the past 5 years that is likely to preclude
             study treatment or comparisons except for nonmelanoma skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified
Clinical trial NCT00236899 (phase 3, status: completed)
Conditions: metastatic breast cancer (mbc)
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, docetaxel, paclitaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic diagnosis of metastatic breast cancer (MBC).

          -  Prior neoadjuvant or adjuvant taxanes regimen is allowed if ≥12 months since
             completion of the regimen.

          -  Relapsing after receiving one adjuvant/neoadjuvant chemotherapy containing an
             anthracycline if not clinically contraindicated.

          -  Patients with measurable disease.

          -  Previous hormonal therapy for adjuvant setting or metastatic disease.

        Exclusion Criteria:

          -  Previous chemotherapy for MBC

          -  Previous chemotherapy with gemcitabine in any setting of disease

          -  Patient candidable to treatment with trastuzumab.
Clinical trial NCT00172042 (phase 3, status: completed)
Conditions: non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: zoledronic acid 4 mg
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed Non-small Cell Lung Cancer (NSCLC)

          -  Newly Diagnosed, Stage IIIA and Stage IIIB excluding patients with pleural effusion

          -  Patients must have received primary treatment for their disease and had no progression

        Exclusion Criteria:

          -  Diagnosed with NSCLC longer than 6 months ago

          -  Treatment with other bisphosphonates in past 12 months

          -  Presence of metastases

        Other protocol-defined inclusion and exclusion criteria may apply.
Clinical trial NCT00504881 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: placebo, brivaracetam
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects were aged from 16 to 70 years, inclusive. Subjects under 18 years of age were
             only included where legally permitted and ethically accepted

          -  Subjects had well-characterized localization-related Epilepsy or generalized Epilepsy
             according to the International League Against Epilepsy (ILAE) classification

          -  For subjects suffering from localization-related Epilepsy: subjects had at least 2
             Partial-Onset Seizures (POSs) whether or not secondarily generalized per month during
             the 3 months preceding Visit 1 according to the ILAE classification

          -  For subjects suffering from localization-related Epilepsy: subjects had at least 4
             Partial-Onset Seizures (POSs) whether or not secondarily generalized during the 4-week
             Baseline Period according to the ILAE classification

          -  For subjects suffering from generalized Epilepsy: subjects had at least 2 Type
             II-seizure days per month during the 3 months preceding Visit 1 according to the ILAE
             classification

          -  For subjects suffering from generalized Epilepsy: subjects had at least 4 Type
             II-seizure days during the 4 week Baseline Period according to the ILAE classification

          -  Subjects were uncontrolled while treated by 1 to 3 permitted concomitant Antiepileptic
             Drugs (AEDs). Vagal nerve stimulation was allowed and was not counted as a concomitant
             AED

        Exclusion Criteria:

          -  For subjects who suffered from localization-related Epilepsy: history or presence of
             Seizures occurring only in clusters (too frequently or indistinctly separated to be
             reliably counted) before Visit 2 or occurring only as Type IA non-motor

          -  Subjects with a history or presence of Status Epilepticus during the year preceding
             Visit 1 or during Baseline
Clinical trial NCT01511809 (phase 3, status: completed)
Conditions: hiv-1 infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: atazanavir/ritonavir monotherapy
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV infected patients

          -  age > 18 years

          -  On treatment with ATV/r plus 2 NRTIs for at least 48 weeks

          -  Virological suppression (HIV-RNA<50 c/ml) by at least 24 weeks with ATV/r plus 2 NRTIs

          -  No virologic failure after the initiation of the first antiretroviral therapy.
             Previous treatment changes due to toxicity or treatment simplifications will be
             permitted only if occurred with documented virological suppression.

          -  CD4 cells nadir >100 cells/µL

          -  PPI and H2-receptor antagonists as follows: the proton-pump inhibitors should not be
             used; if H2-receptor antagonists are co-administered, a dose equivalent to famotidine
             20 mg BID should not be exceeded.

        Exclusion Criteria:

          -  Pregnancy and breast feeding women

          -  AIDS defining events

          -  Evidence of active HBV infection (HBsAg positive)

          -  Previous virological failure

          -  History of resistance to ATV

          -  Use of contraindicated medications
Clinical trial NCT00634725 (phase 3, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: capecitabine, erlotinib hydrochloride, gemcitabine hydrochloride
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the pancreas meeting the following
             criteria:

               -  De novo locally advanced disease

               -  Unresectable disease

               -  Stage III according to the UICC classification

                    -  No distant metastases

                    -  No localized stage IA-IIB or metastatic stage IV disease according to UICC
                       classification

               -  Not considered for curative resection after pluridisciplinary discussion

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 12 weeks

          -  Polynuclear neutrophils ≥ 1.5 x 10^9/L

          -  Platelets ≥ 100 x 10^9/L

          -  Hemoglobin ≥ 9 g/dL

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

               -  For patients who have had a recent biliary drain and whose bilirubin is
                  descending, a value of ≤ 3 times ULN is acceptable

          -  Creatinine ≤ 2 mg/dL

          -  AST and ALT ≤ 2.5 times ULN

          -  Alkaline phosphatase ≤ 5 times ULN

          -  Albumin ≥ 25 g/L

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of therapy

        Exclusion criteria:

          -  Diarrhea ≥ grade 2 and/or uncontrolled diarrhea

          -  Affiliated with a social security regime

          -  Unable to follow instructions for psychological, familial, or geographical reasons

          -  Allergic to one of the ingredients in erlotinib hydrochloride

          -  Cancer within the past 5 years, except for in situ cancer of the neck of the uterus or
             basal cell skin cancer

          -  Severe infection

          -  Ophthalmic disease (i.e., inflammation, keratopathy, or infection)

          -  Symptomatic coronary or cardiac insufficiency, myocardial infarction, or stroke within
             the last 6 months

          -  Unable to take oral treatments

          -  Gastrointestinal disorders that could be associated with absorption disorders

          -  Untreated gastric or duodenal ulcer

        PRIOR CONCURRENT THERAPY:

          -  No prior radiotherapy (including abdominal radiotherapy) or chemotherapy for any
             reason

          -  No prior anti-epidermal growth factor-receptor therapy
Clinical trial NCT00108082 (phase 3, status: completed)
Conditions: hypertrophy, left ventricular
ICD codes: J35.3, J35.1, J35.2, N28.81, N62, N85.2, J34.3
Drugs: carvedilol mr, atenolol, lisinopril
SMILES: COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2, CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1, CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
Eligibility criteria:

        Inclusion criteria:

          -  Stage 1 or Stage 2 hypertension.

          -  Left ventricular hypertrophy.

        Exclusion criteria:

          -  In atrial fibrillation.

          -  Takes beta-blocker for MI (myocardial infarction) or arrhythmia.

          -  Has uncontrolled diabetes, uncontrollable or symptomatic arrhythmias, unstable angina,
             second or third degree heart block, history of MI, COPD (chronic obstructive pulmonary
             disease), liver or kidney disease.

          -  Uses beta-2-agonists.

          -  Unable to undergo MRI (magnetic resonance imaging).

          -  Females of childbearing potential.
Clinical trial NCT00106028 (phase 3, status: completed)
Conditions: osteogenesis imperfecta
ICD codes: Q78.0
Drugs: risedronate sodium (actonel), placebo
SMILES: OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  OI diagnosis

          -  increased risk of fracture: either has a history of at least 1 radiographically
             confirmed, non-traumatic or low impact fracture plus low bone mineral density (BMD) or
             has very low BMD with or without a history of fractures.

        Exclusion Criteria:

          -  Any bisphosphonate use within one year of enrollment
Clinical trial NCT00125918 (phase 3, status: completed)
Conditions: pulmonary hypertension
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: tadalafil, tadalafil, tadalafil, tadalafil, placebo
SMILES: [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  At least 12 years of age.

          -  Body weight at least 40 kg (approximately 88 pounds).

          -  Pulmonary hypertension (PAH) that is either idiopathic; related to collagen vascular
             disease; related to anorexigen use; associated with an atrial septal defect (resting
             SaO2 greater than or equal to 88%); with surgical repair, of at least 1 year duration,
             of a congenital systemic-to-pulmonary shunt.

          -  If on bosentan, must be at the maximal dose of 125 mg twice daily for a minimum of 12
             weeks prior to screening and have an AST/ALT less than 3 times normal.

          -  History of PAH established by a resting mean pulmonary artery pressure greater than or
             equal to 25 mm Hg, pulmonary artery wedge pressure less than or equal to 15 mm Hg, and
             pulmonary vascular resistance greater than or equal to 3 Wood units via right heart
             catheterization

          -  Have World Health Organization functional class I, II, III or IV status.

          -  Have a qualifying 6-minute walk test distance at screening

          -  Have no evidence of significant parenchymal lung disease

        Exclusion Criteria:

          -  Are nursing or pregnant.

          -  PAH due to conditions other than noted in the above inclusion criteria.

          -  History of left-sided heart disease.

          -  History of atrial septostomy within 3 months before study entry

          -  History of angina pectoris or other condition that was treated with long-or
             short-acting nitrates within 12 weeks before administration of study drug.

          -  History of symptomatic coronary disease.

          -  Have any therapy with a prostacyclin or analogue, L-arginine, phosphodiesterase (PDE)
             inhibitor, or investigational drug within 4 weeks before administration of study drug.
Clinical trial NCT01499095 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: lantus (insulin glargine), hoe901-u300 (new formulation of insulin glargine)
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion criteria :

          -  Participants with type 2 diabetes mellitus

          -  Substudy inclusion criteria:

               -  Completion of the 6-month study period in main study (Visit 10)

               -  Randomized and treated with insulin glargine new formulation during the 6- month
                  treatment period (Baseline - Month 6)

        Exclusion criteria:

          -  Age less than (<) 18 years

          -  HbA1c <7.0% or greater than (>) 10% at screening

          -  Diabetes other than type 2 diabetes mellitus

          -  Less than 6 months on basal insulin treatment together with oral antihyperglycemic
             drug(s) and self-monitoring of blood glucose

          -  Participants using sulfonylurea in the last 2 months before screening visit

          -  Any contraindication to use of insulin glargine as defined in the national product
             label

          -  Use of insulin pump in the last 6 months before screening

          -  Initiation of new glucose-lowering medications in the last 3 months before screening
             visit

          -  History or presence of significant diabetic retinopathy or macular edema likely to
             require laser or injectable drugs or surgical treatment during the study period

          -  Pregnant or breast-feeding women or women who intend to become pregnant during the
             study period

          -  Substudy exclusion criteria:

               -  Participant not willing to use the adaptable injection intervals on at least two
                  days per week

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.